Use of GL-ONC1 in Patients With Advanced Cancers With No Standard of Care

Trial Profile

Use of GL-ONC1 in Patients With Advanced Cancers With No Standard of Care

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs GL ONC1 (Primary)
  • Indications Acute myeloid leukaemia; Cancer; Solid tumours
  • Focus Expanded access; Therapeutic Use
  • Sponsors Genelux Corporation
  • Most Recent Events

    • 07 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top